Your browser doesn't support javascript.
loading
Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors.
Sato, Jun; Shimizu, Toshio; Koyama, Takafumi; Iwasa, Satoru; Shimomura, Akihiko; Kondo, Shunsuke; Kitano, Shigehisa; Yonemori, Kan; Fujiwara, Yutaka; Tamura, Kenji; Suzuki, Takuya; Takase, Takao; Nagai, Reiko; Yamaguchi, Kohei; Semba, Taro; Zhao, Zi-Ming; Ren, Min; Yamamoto, Noboru.
Afiliação
  • Sato J; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Shimizu T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Koyama T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Iwasa S; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Shimomura A; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
  • Kondo S; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Kitano S; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Yonemori K; Division of Cancer Immunotherapy Development, Advanced Medical Development Center, The Cancer Institute Hospital of JFCR, Tokyo, Japan.
  • Fujiwara Y; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Tamura K; Department of Thoracic Oncology, Aichi Cancer Center, Nagoya, Japan.
  • Suzuki T; Department of Respiratory Medicine and Medical Oncology, Faculty of Medicine, Shimane University Hospital, Tokyo, Japan.
  • Takase T; Japan and Asia Clinical Development Department, Oncology Business Group, Eisai Co., Ltd., Tokyo, Japan.
  • Nagai R; Clinical Data Science Department, Medicine Development Center, Eisai Co., Ltd., Tokyo, Japan.
  • Yamaguchi K; Clinical Data Science Department, Medicine Development Center, Eisai Co., Ltd., Tokyo, Japan.
  • Semba T; Clinical Pharmacology Science Department, Medicine Development Center, Eisai Co., Ltd., Tokyo, Japan.
  • Zhao ZM; Tsukuba Research Department, Oncology Business Group, Eisai Co., Ltd., Ibaraki, Japan.
  • Ren M; Translational Science, Oncology Business Group, Eisai Inc., Nutley, New Jersey.
  • Yamamoto N; Biostats, Oncology Business Group, Eisai Inc., Nutley, New Jersey.
Clin Cancer Res ; 28(9): 1783-1791, 2022 05 02.
Article em En | MEDLINE | ID: mdl-35180771
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fator A de Crescimento do Endotélio Vascular / Neoplasias Limite: Adult / Humans País/Região como assunto: Asia Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fator A de Crescimento do Endotélio Vascular / Neoplasias Limite: Adult / Humans País/Região como assunto: Asia Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão